Stockscreener 앱 받기
1.28
11.11%
-0.16
시간 외 거래:
1.27
-0.01
-0.78%
전일 마감가:
$1.44
열려 있는:
$1.44
하루 거래량:
383.00K
Relative Volume:
0.44
시가총액:
$147.26M
수익:
$27.08M
순이익/손실:
$-37.00M
주가수익비율:
-2.4615
EPS:
-0.52
순현금흐름:
$-18.46M
1주 성능:
-5.88%
1개월 성능:
-8.57%
6개월 성능:
-42.34%
1년 성능:
-5.88%
1일 변동 폭
$1.28
$1.45
1주일 범위
$1.27
$1.49
52주 변동 폭
$0.9515
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.28 | 147.26M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Acquired by JPMorgan Chase & Co. - Defense World
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo
Geode Capital Management LLC Reduces Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
XTX Topco Ltd Acquires New Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 34.8% in April - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Aclaris Therapeutics Names Jesse Hall Chief Medical Officer - marketscreener.com
Aclaris Therapeutics (ACRS) Welcomes Jesse Hall as Chief Medical Officer | ACRS Stock News - GuruFocus
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer - marketscreener.com
Aclaris Therapeutics appoints new Chief Medical Officer - Investing.com
Aclaris Strengthens Leadership: Humira and Prolia Developer Takes CMO Role to Advance Immunology Pipeline - Stock Titan
Androgenetic Alopecia Treatment Market Generated - openPR.com
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.67 Average Target Price from Brokerages - Defense World
Strong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance
Aclaris Therapeutics Inc [ACRS] Records 50-Day SMA of $1.6630 - knoxdaily.com
The time has not yet come to remove your chips from the table: Aclaris Therapeutics Inc (ACRS) - Sete News
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MSN
Trading Day Triumph: Aclaris Therapeutics Inc (ACRS) Ends at 1.10, a -2.65 Surge/Plunge - DWinneX
Some Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shareholders Look For Exit As Shares Take 31% Pounding - simplywall.st
Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052 - Yahoo Finance
FDA clears Aclaris’ new drug for clinical trial - Investing.com Australia
FDA clears Aclaris’ new drug for clinical trial By Investing.com - Investing.com South Africa
ACRS’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Aclaris Therapeutics gets FDA nod to begin trial of ATI-052 - MSN
Aclaris Gets FDA Clearance for Clinical Trial of Immuno-Inflammatory Treatment - marketscreener.com
Aclaris Therapeutics (ACRS) Gains on FDA Clearance for ATI-052 Trial - GuruFocus
Aclaris gets FDA nod to begin trial of ATI-052 (ACRS:NASDAQ) - Seeking Alpha
Aclaris Therapeutics Shares Rise After FDA Clear ATI-052 for Trial - marketscreener.com
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody - The Manila Times
Aclaris Therapeutics (ACRS) Gains FDA Clearance for Novel Antibody Trial | ACRS Stock News - GuruFocus
Aclaris Therapeutics Secures U.S. Food and Drug - GlobeNewswire
Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com
Arthralgia Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis - The Globe and Mail
Commonwealth Equity Services LLC Buys New Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN
Aclaris Therapeutics Inc (ACRS) Has Recovered 21.49% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
Aclaris Therapeutics Inc [ACRS] Director makes an insider purchase of 666,666 shares worth 1.5 million. - knoxdaily.com
Raymond James Financial Inc. Acquires Shares of 154,351 Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) see US$21m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Charles Schwab Investment Management Inc. Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.67 - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - Defense World
Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely? - Yahoo Finance
HighTower Advisors LLC Has $652,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris at H.C. Wainwright Conference: Strategic Moves in Immuno-Inflammatory Diseases - Investing.com India
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):